Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Cancer Drug Discovery and Development is Scopus-indexed (Q4, CiteScore 0.5). Published by Humana Press Inc..
Checked against the index lists dated .
ISSN 2196-9906Verify ISSN ↗2196-9914Verify ISSN ↗
Publisher: Humana Press Inc.
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Oncology | 376 / 428 | 12th | Q4 |
| Cancer Research | 220 / 233 | 5th | Q4 |
| Drug Discovery | 153 / 161 | 5th | Q4 |
Not listed in: Web of Science, DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2024–present (also 2022, 2014–2020), best quartile Q4, CiteScore 0.5.
Cancer Drug Discovery and Development is Q4 in Oncology (rank 376 of 428), Q4 in Cancer Research (rank 220 of 233) and Q4 in Drug Discovery (rank 153 of 161), by CiteScore 2025.
Cancer Drug Discovery and Development is not in the Web of Science Core Collection (SCIE, SSCI, AHCI or ESCI), so Clarivate publishes no Journal Impact Factor for it. Its Scopus CiteScore is 0.5, quartile Q4, 12th percentile. Any "impact factor" quoted elsewhere is not the Clarivate metric.
Cancer Drug Discovery and Development is published by Humana Press Inc. Its print ISSN is 2196-9906 and its online ISSN is 2196-9914.
No — it is not currently in the Web of Science core collections (SCIE, SSCI, AHCI or ESCI).
No — it is not registered as an open-access journal in DOAJ or Scopus.
Cancer Drug Discovery and Development has an h-index of 16 and a 2-year mean of 0.77 citations per paper (OpenAlex). Its Scopus CiteScore is 0.5, quartile Q4. On 2-year citations it ranks #307 of 424 Scopus journals in Oncology.
Cancer Drug Discovery and Development published 34 papers in 2025; its busiest recent year was 2017 with 48. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.